Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis
Objective Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childh...
Gespeichert in:
Veröffentlicht in: | Lupus 2022-01, Vol.31 (1), p.97-104 |
---|---|
Hauptverfasser: | , , , , , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 104 |
---|---|
container_issue | 1 |
container_start_page | 97 |
container_title | Lupus |
container_volume | 31 |
creator | Andrade Balbi, Verena Artur Silva, Clovis Nascimento Pedrosa, Tatiana Maria Rodrigues Pereira, Rosa Maria de Arruda Campos, Lucia Pires Leon, Elaine Duarte, Nilo Melechco Carvalho, Valdemir Gofinet Pasoto, Sandra Cordeiro do Rosário, Debora Kolachinski Brandao, Leticia I Brunner, Hermine Bonfá, Eloisa Emi Aikawa, Nadia |
description | Objective
Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childhood-onset lupus nephritis (LN).
Methods
Sixty LN patients on HCQ use for at least 6-months were prospectively evaluated at baseline (BL) and about 6-months later for cSLE flare and HCQ blood levels (ng/mL) measured by liquid chromatography-tandem mass spectrometry.
Results
There were 19 patients (32%) with flare, during the study with median SLEDAI increase of 4 (0–8). Median (IQR) BL HCQ levels of the flare group were lower compared to stable patients [557.5 (68.6–980.3) vs. 1061.9 (534.8–1590.0 ng/mL); p=0.012]. ROC curve analysis demonstrated that HCQ levels≤1075 ng/mL were associated with a 5.08 (95%CI 1.28-20.13; p=0.021) times increased risk of flare. Six-month HCQ levels revealed that most patients 24/54 (44%) had persistently low levels (≤1075) during follow-up. Among those, 11/24 (46%) had flare. Multiple logistic regression analysis including prednisone use, baseline SLEDAI-2K, adherence based on pharmacy refill and BL HCQ blood levels as possible predictors of flare revealed that only HCQ blood level was independently associated with flare (OR 0.999, 95%CI 0.998-1.0, p=0.013).
Conclusions
We demonstrated that HCQ blood cut-off level under 1075 ng/mL predicts flare in childhood-onset LN patients under prescribed HCQ dose of 4.0–5.5 mg/kg/day. We further observed that most of these patients have compliance issues reinforcing the need for a close surveillance particularly in those with levels below the defined cut-off. |
doi_str_mv | 10.1177/09612033211062515 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2615476923</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_09612033211062515</sage_id><sourcerecordid>2615476923</sourcerecordid><originalsourceid>FETCH-LOGICAL-c368t-e9a2d80f5265bdb4a60480f05b6456a4f53ac8630915738cebcbdf423d3050373</originalsourceid><addsrcrecordid>eNp1kF9LwzAUxYMobk4_gC8S8MWXzvxP-yhDnTAQQZ9LmqS2I2tq0or79rZsKig-XS73d849HADOMZpjLOU1ygQmiFKCMRKEY34ApphJmQwHcgim4z0ZgQk4iXGNEKI4E8dgQlkmuEzJFDwttyb4j62unA_-ra8bCwvnvYHOvlsXYRusqXUXYelUsLBuoK5qZ6oBSXwTbQdd3_YRNratQt3V8RQclcpFe7afM_Byd_u8WCarx_uHxc0q0VSkXWIzRUyKSk4EL0zBlEBsWBEvBONCsZJTpVNBUYa5pKm2hS5MyQg1FHFEJZ2Bq51vO-a2scs3ddTWOdVY38ecCMyZFBmhA3r5C137PjRDuoEiRApGxGiId5QOPsZgy7wN9UaFbY5RPvad_-l70FzsnftiY8234qvgAZjvgKhe7c_b_x0_AcXNh00</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2622764267</pqid></control><display><type>article</type><title>Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis</title><source>MEDLINE</source><source>SAGE Complete</source><creator>Andrade Balbi, Verena ; Artur Silva, Clovis ; Nascimento Pedrosa, Tatiana ; Maria Rodrigues Pereira, Rosa ; Maria de Arruda Campos, Lucia ; Pires Leon, Elaine ; Duarte, Nilo ; Melechco Carvalho, Valdemir ; Gofinet Pasoto, Sandra ; Cordeiro do Rosário, Debora ; Kolachinski Brandao, Leticia ; I Brunner, Hermine ; Bonfá, Eloisa ; Emi Aikawa, Nadia</creator><creatorcontrib>Andrade Balbi, Verena ; Artur Silva, Clovis ; Nascimento Pedrosa, Tatiana ; Maria Rodrigues Pereira, Rosa ; Maria de Arruda Campos, Lucia ; Pires Leon, Elaine ; Duarte, Nilo ; Melechco Carvalho, Valdemir ; Gofinet Pasoto, Sandra ; Cordeiro do Rosário, Debora ; Kolachinski Brandao, Leticia ; I Brunner, Hermine ; Bonfá, Eloisa ; Emi Aikawa, Nadia</creatorcontrib><description>Objective
Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childhood-onset lupus nephritis (LN).
Methods
Sixty LN patients on HCQ use for at least 6-months were prospectively evaluated at baseline (BL) and about 6-months later for cSLE flare and HCQ blood levels (ng/mL) measured by liquid chromatography-tandem mass spectrometry.
Results
There were 19 patients (32%) with flare, during the study with median SLEDAI increase of 4 (0–8). Median (IQR) BL HCQ levels of the flare group were lower compared to stable patients [557.5 (68.6–980.3) vs. 1061.9 (534.8–1590.0 ng/mL); p=0.012]. ROC curve analysis demonstrated that HCQ levels≤1075 ng/mL were associated with a 5.08 (95%CI 1.28-20.13; p=0.021) times increased risk of flare. Six-month HCQ levels revealed that most patients 24/54 (44%) had persistently low levels (≤1075) during follow-up. Among those, 11/24 (46%) had flare. Multiple logistic regression analysis including prednisone use, baseline SLEDAI-2K, adherence based on pharmacy refill and BL HCQ blood levels as possible predictors of flare revealed that only HCQ blood level was independently associated with flare (OR 0.999, 95%CI 0.998-1.0, p=0.013).
Conclusions
We demonstrated that HCQ blood cut-off level under 1075 ng/mL predicts flare in childhood-onset LN patients under prescribed HCQ dose of 4.0–5.5 mg/kg/day. We further observed that most of these patients have compliance issues reinforcing the need for a close surveillance particularly in those with levels below the defined cut-off.</description><identifier>ISSN: 0961-2033</identifier><identifier>EISSN: 1477-0962</identifier><identifier>DOI: 10.1177/09612033211062515</identifier><identifier>PMID: 34965782</identifier><language>eng</language><publisher>London, England: SAGE Publications</publisher><subject>Adult ; Antirheumatic Agents - therapeutic use ; Blood levels ; Children ; Chromatography, Liquid ; Humans ; Hydroxychloroquine ; Hydroxychloroquine - blood ; Hydroxychloroquine - therapeutic use ; Liquid chromatography ; Lupus ; Lupus Erythematosus, Systemic - drug therapy ; Lupus nephritis ; Lupus Nephritis - diagnosis ; Lupus Nephritis - drug therapy ; Mass spectroscopy ; Morbidity ; Nephritis ; Prednisone ; Systemic lupus erythematosus</subject><ispartof>Lupus, 2022-01, Vol.31 (1), p.97-104</ispartof><rights>The Author(s) 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c368t-e9a2d80f5265bdb4a60480f05b6456a4f53ac8630915738cebcbdf423d3050373</citedby><cites>FETCH-LOGICAL-c368t-e9a2d80f5265bdb4a60480f05b6456a4f53ac8630915738cebcbdf423d3050373</cites><orcidid>0000-0002-3723-5028 ; 0000-0001-9250-6508 ; 0000-0002-0520-4681 ; 0000-0002-7585-4348 ; 0000-0001-9653-0468</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/09612033211062515$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/09612033211062515$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,776,780,21798,27901,27902,43597,43598</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34965782$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Andrade Balbi, Verena</creatorcontrib><creatorcontrib>Artur Silva, Clovis</creatorcontrib><creatorcontrib>Nascimento Pedrosa, Tatiana</creatorcontrib><creatorcontrib>Maria Rodrigues Pereira, Rosa</creatorcontrib><creatorcontrib>Maria de Arruda Campos, Lucia</creatorcontrib><creatorcontrib>Pires Leon, Elaine</creatorcontrib><creatorcontrib>Duarte, Nilo</creatorcontrib><creatorcontrib>Melechco Carvalho, Valdemir</creatorcontrib><creatorcontrib>Gofinet Pasoto, Sandra</creatorcontrib><creatorcontrib>Cordeiro do Rosário, Debora</creatorcontrib><creatorcontrib>Kolachinski Brandao, Leticia</creatorcontrib><creatorcontrib>I Brunner, Hermine</creatorcontrib><creatorcontrib>Bonfá, Eloisa</creatorcontrib><creatorcontrib>Emi Aikawa, Nadia</creatorcontrib><title>Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis</title><title>Lupus</title><addtitle>Lupus</addtitle><description>Objective
Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childhood-onset lupus nephritis (LN).
Methods
Sixty LN patients on HCQ use for at least 6-months were prospectively evaluated at baseline (BL) and about 6-months later for cSLE flare and HCQ blood levels (ng/mL) measured by liquid chromatography-tandem mass spectrometry.
Results
There were 19 patients (32%) with flare, during the study with median SLEDAI increase of 4 (0–8). Median (IQR) BL HCQ levels of the flare group were lower compared to stable patients [557.5 (68.6–980.3) vs. 1061.9 (534.8–1590.0 ng/mL); p=0.012]. ROC curve analysis demonstrated that HCQ levels≤1075 ng/mL were associated with a 5.08 (95%CI 1.28-20.13; p=0.021) times increased risk of flare. Six-month HCQ levels revealed that most patients 24/54 (44%) had persistently low levels (≤1075) during follow-up. Among those, 11/24 (46%) had flare. Multiple logistic regression analysis including prednisone use, baseline SLEDAI-2K, adherence based on pharmacy refill and BL HCQ blood levels as possible predictors of flare revealed that only HCQ blood level was independently associated with flare (OR 0.999, 95%CI 0.998-1.0, p=0.013).
Conclusions
We demonstrated that HCQ blood cut-off level under 1075 ng/mL predicts flare in childhood-onset LN patients under prescribed HCQ dose of 4.0–5.5 mg/kg/day. We further observed that most of these patients have compliance issues reinforcing the need for a close surveillance particularly in those with levels below the defined cut-off.</description><subject>Adult</subject><subject>Antirheumatic Agents - therapeutic use</subject><subject>Blood levels</subject><subject>Children</subject><subject>Chromatography, Liquid</subject><subject>Humans</subject><subject>Hydroxychloroquine</subject><subject>Hydroxychloroquine - blood</subject><subject>Hydroxychloroquine - therapeutic use</subject><subject>Liquid chromatography</subject><subject>Lupus</subject><subject>Lupus Erythematosus, Systemic - drug therapy</subject><subject>Lupus nephritis</subject><subject>Lupus Nephritis - diagnosis</subject><subject>Lupus Nephritis - drug therapy</subject><subject>Mass spectroscopy</subject><subject>Morbidity</subject><subject>Nephritis</subject><subject>Prednisone</subject><subject>Systemic lupus erythematosus</subject><issn>0961-2033</issn><issn>1477-0962</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kF9LwzAUxYMobk4_gC8S8MWXzvxP-yhDnTAQQZ9LmqS2I2tq0or79rZsKig-XS73d849HADOMZpjLOU1ygQmiFKCMRKEY34ApphJmQwHcgim4z0ZgQk4iXGNEKI4E8dgQlkmuEzJFDwttyb4j62unA_-ra8bCwvnvYHOvlsXYRusqXUXYelUsLBuoK5qZ6oBSXwTbQdd3_YRNratQt3V8RQclcpFe7afM_Byd_u8WCarx_uHxc0q0VSkXWIzRUyKSk4EL0zBlEBsWBEvBONCsZJTpVNBUYa5pKm2hS5MyQg1FHFEJZ2Bq51vO-a2scs3ddTWOdVY38ecCMyZFBmhA3r5C137PjRDuoEiRApGxGiId5QOPsZgy7wN9UaFbY5RPvad_-l70FzsnftiY8234qvgAZjvgKhe7c_b_x0_AcXNh00</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Andrade Balbi, Verena</creator><creator>Artur Silva, Clovis</creator><creator>Nascimento Pedrosa, Tatiana</creator><creator>Maria Rodrigues Pereira, Rosa</creator><creator>Maria de Arruda Campos, Lucia</creator><creator>Pires Leon, Elaine</creator><creator>Duarte, Nilo</creator><creator>Melechco Carvalho, Valdemir</creator><creator>Gofinet Pasoto, Sandra</creator><creator>Cordeiro do Rosário, Debora</creator><creator>Kolachinski Brandao, Leticia</creator><creator>I Brunner, Hermine</creator><creator>Bonfá, Eloisa</creator><creator>Emi Aikawa, Nadia</creator><general>SAGE Publications</general><general>Sage Publications Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-3723-5028</orcidid><orcidid>https://orcid.org/0000-0001-9250-6508</orcidid><orcidid>https://orcid.org/0000-0002-0520-4681</orcidid><orcidid>https://orcid.org/0000-0002-7585-4348</orcidid><orcidid>https://orcid.org/0000-0001-9653-0468</orcidid></search><sort><creationdate>202201</creationdate><title>Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis</title><author>Andrade Balbi, Verena ; Artur Silva, Clovis ; Nascimento Pedrosa, Tatiana ; Maria Rodrigues Pereira, Rosa ; Maria de Arruda Campos, Lucia ; Pires Leon, Elaine ; Duarte, Nilo ; Melechco Carvalho, Valdemir ; Gofinet Pasoto, Sandra ; Cordeiro do Rosário, Debora ; Kolachinski Brandao, Leticia ; I Brunner, Hermine ; Bonfá, Eloisa ; Emi Aikawa, Nadia</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c368t-e9a2d80f5265bdb4a60480f05b6456a4f53ac8630915738cebcbdf423d3050373</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Adult</topic><topic>Antirheumatic Agents - therapeutic use</topic><topic>Blood levels</topic><topic>Children</topic><topic>Chromatography, Liquid</topic><topic>Humans</topic><topic>Hydroxychloroquine</topic><topic>Hydroxychloroquine - blood</topic><topic>Hydroxychloroquine - therapeutic use</topic><topic>Liquid chromatography</topic><topic>Lupus</topic><topic>Lupus Erythematosus, Systemic - drug therapy</topic><topic>Lupus nephritis</topic><topic>Lupus Nephritis - diagnosis</topic><topic>Lupus Nephritis - drug therapy</topic><topic>Mass spectroscopy</topic><topic>Morbidity</topic><topic>Nephritis</topic><topic>Prednisone</topic><topic>Systemic lupus erythematosus</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Andrade Balbi, Verena</creatorcontrib><creatorcontrib>Artur Silva, Clovis</creatorcontrib><creatorcontrib>Nascimento Pedrosa, Tatiana</creatorcontrib><creatorcontrib>Maria Rodrigues Pereira, Rosa</creatorcontrib><creatorcontrib>Maria de Arruda Campos, Lucia</creatorcontrib><creatorcontrib>Pires Leon, Elaine</creatorcontrib><creatorcontrib>Duarte, Nilo</creatorcontrib><creatorcontrib>Melechco Carvalho, Valdemir</creatorcontrib><creatorcontrib>Gofinet Pasoto, Sandra</creatorcontrib><creatorcontrib>Cordeiro do Rosário, Debora</creatorcontrib><creatorcontrib>Kolachinski Brandao, Leticia</creatorcontrib><creatorcontrib>I Brunner, Hermine</creatorcontrib><creatorcontrib>Bonfá, Eloisa</creatorcontrib><creatorcontrib>Emi Aikawa, Nadia</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>MEDLINE - Academic</collection><jtitle>Lupus</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Andrade Balbi, Verena</au><au>Artur Silva, Clovis</au><au>Nascimento Pedrosa, Tatiana</au><au>Maria Rodrigues Pereira, Rosa</au><au>Maria de Arruda Campos, Lucia</au><au>Pires Leon, Elaine</au><au>Duarte, Nilo</au><au>Melechco Carvalho, Valdemir</au><au>Gofinet Pasoto, Sandra</au><au>Cordeiro do Rosário, Debora</au><au>Kolachinski Brandao, Leticia</au><au>I Brunner, Hermine</au><au>Bonfá, Eloisa</au><au>Emi Aikawa, Nadia</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis</atitle><jtitle>Lupus</jtitle><addtitle>Lupus</addtitle><date>2022-01</date><risdate>2022</risdate><volume>31</volume><issue>1</issue><spage>97</spage><epage>104</epage><pages>97-104</pages><issn>0961-2033</issn><eissn>1477-0962</eissn><abstract>Objective
Low hydroxychloroquine (HCQ) blood levels are predictors of flare in adult lupus. Childhood-onset systemic lupus erythematosus (cSLE) has high morbidity with renal involvement in up to 80% of cases. The aim of this study is to determine the HCQ cut-off levels which predicts flare in childhood-onset lupus nephritis (LN).
Methods
Sixty LN patients on HCQ use for at least 6-months were prospectively evaluated at baseline (BL) and about 6-months later for cSLE flare and HCQ blood levels (ng/mL) measured by liquid chromatography-tandem mass spectrometry.
Results
There were 19 patients (32%) with flare, during the study with median SLEDAI increase of 4 (0–8). Median (IQR) BL HCQ levels of the flare group were lower compared to stable patients [557.5 (68.6–980.3) vs. 1061.9 (534.8–1590.0 ng/mL); p=0.012]. ROC curve analysis demonstrated that HCQ levels≤1075 ng/mL were associated with a 5.08 (95%CI 1.28-20.13; p=0.021) times increased risk of flare. Six-month HCQ levels revealed that most patients 24/54 (44%) had persistently low levels (≤1075) during follow-up. Among those, 11/24 (46%) had flare. Multiple logistic regression analysis including prednisone use, baseline SLEDAI-2K, adherence based on pharmacy refill and BL HCQ blood levels as possible predictors of flare revealed that only HCQ blood level was independently associated with flare (OR 0.999, 95%CI 0.998-1.0, p=0.013).
Conclusions
We demonstrated that HCQ blood cut-off level under 1075 ng/mL predicts flare in childhood-onset LN patients under prescribed HCQ dose of 4.0–5.5 mg/kg/day. We further observed that most of these patients have compliance issues reinforcing the need for a close surveillance particularly in those with levels below the defined cut-off.</abstract><cop>London, England</cop><pub>SAGE Publications</pub><pmid>34965782</pmid><doi>10.1177/09612033211062515</doi><tpages>8</tpages><orcidid>https://orcid.org/0000-0002-3723-5028</orcidid><orcidid>https://orcid.org/0000-0001-9250-6508</orcidid><orcidid>https://orcid.org/0000-0002-0520-4681</orcidid><orcidid>https://orcid.org/0000-0002-7585-4348</orcidid><orcidid>https://orcid.org/0000-0001-9653-0468</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0961-2033 |
ispartof | Lupus, 2022-01, Vol.31 (1), p.97-104 |
issn | 0961-2033 1477-0962 |
language | eng |
recordid | cdi_proquest_miscellaneous_2615476923 |
source | MEDLINE; SAGE Complete |
subjects | Adult Antirheumatic Agents - therapeutic use Blood levels Children Chromatography, Liquid Humans Hydroxychloroquine Hydroxychloroquine - blood Hydroxychloroquine - therapeutic use Liquid chromatography Lupus Lupus Erythematosus, Systemic - drug therapy Lupus nephritis Lupus Nephritis - diagnosis Lupus Nephritis - drug therapy Mass spectroscopy Morbidity Nephritis Prednisone Systemic lupus erythematosus |
title | Hydroxychloroquine blood levels predicts flare in childhood-onset lupus nephritis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T14%3A26%3A00IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hydroxychloroquine%20blood%20levels%20predicts%20flare%20in%20childhood-onset%20lupus%20nephritis&rft.jtitle=Lupus&rft.au=Andrade%20Balbi,%20Verena&rft.date=2022-01&rft.volume=31&rft.issue=1&rft.spage=97&rft.epage=104&rft.pages=97-104&rft.issn=0961-2033&rft.eissn=1477-0962&rft_id=info:doi/10.1177/09612033211062515&rft_dat=%3Cproquest_cross%3E2615476923%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2622764267&rft_id=info:pmid/34965782&rft_sage_id=10.1177_09612033211062515&rfr_iscdi=true |